Discovery of Tricyclic Clerodane Diterpenes as Sarco/Endoplasmic Reticulum Ca2+-ATPase Inhibitors and Structure−Activity Relationships

 

Guardado en:
Detalles Bibliográficos
Autores: De Ford, Christian, Calderón Castro, Carlos, Sehgal, Pankaj, Fedosova, Natalya U., Murillo Masís, Renato, Olesen, Claus, Nissen, Poul, Møller, Jesper V., Merfort, Irmgard
Formato: artículo original
Fecha de Publicación:2015
Descripción:Tricyclic clerodane diterpenes (TCDs) are natural compounds that often show potent cytotoxicity for cancer cells, but their mode of action remains elusive. A computationally based similarity search (CDRUG), combined with principal component analysis (ChemGPS-NP) and docking calculations (GOLD 5.2), suggested TCDs to be inhibitors of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump, which is also the target of the sesquiterpene lactone thapsigargin. Biochemical studies were performed with 11 TCDs on purified rabbit skeletal muscle sarcoplasmic reticulum membranes, which are highly enriched with the SERCA1a isoform. Casearborin D (2) exhibited the highest affinity, with a KD value of 2 μM and giving rise to complete inhibition of SERCA1a activity. Structure–activity relationships revealed that functionalization of two acyl side chains (R1 and R4) and the hydrophobicity imparted by the aliphatic chain at C-9, as well as a C-3,C-4 double bond, play crucial roles for inhibitory activity. Docking studies also suggested that hydrophobic interactions in the binding site, especially with Phe256 and Phe834, may be important for a strong inhibitory activity of the TCDs. In conclusion, a novel class of SERCA inhibitory compounds is presented.
País:Kérwá
Institución:Universidad de Costa Rica
Repositorio:Kérwá
OAI Identifier:oai:https://www.kerwa.ucr.ac.cr:10669/75180
Acceso en línea:https://pubs.acs.org/doi/10.1021/acs.jnatprod.5b00062
https://hdl.handle.net/10669/75180
Access Level:acceso abierto
Palabra clave:Tricyclic Clerodane Diterpenes
Natural compounds
Cancer cells
Lymphoblastic leukemia
ATPase activity
Cáncer
610.736 98 Cáncer